## TECH: Bio-Techne Corp - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 -0.9% below STRENGTH zone (3.0-6.0%). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($54.11)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 4
- **Sentiment:** Neutral (Bullish: 0, Bearish: 1)

**1. Thrivent Financial for Lutherans Has $11.53 Million Holdings in Bio-Techne Corp $TECH**
- Source: MarketBeat | 20251218T105948 | Somewhat-Bullish | Relevance: 100%
- Thrivent Financial for Lutherans significantly increased its stake in Bio-Techne Corp, purchasing an additional 47,555 shares to reach a total of 224,006 shares valued at approximately $11.53 million. This move highlights continued institutional interest in Bio-Techne, with other major hedge funds also growing their positions. The company reported Q2 EPS in line with estimates and maintains a "Moderate Buy" analyst rating.

**2. Aaron Wealth Advisors LLC Takes $980,000 Position in Bio-Techne Corp $TECH**
- Source: MarketBeat | 20251218T081231 | Somewhat-Bullish | Relevance: 100%
- Aaron Wealth Advisors LLC has acquired a new stake of 17,611 shares, valued at approximately $980,000, in Bio-Techne Corp (NASDAQ:TECH) during the third quarter. Various other hedge funds also adjusted their holdings in the biotechnology company, and a consensus of analysts has given Bio-Techne an average rating of "Moderate Buy" with a target price of $71.00. The company recently declared a quarterly dividend of $0.08, paid on November 28th.

**3. Bio-Techne stock: Is TECH underperforming the healthcare sector?**
- Source: MSN | 20251217T230907 | Somewhat-Bearish | Relevance: 100%
- This article discusses whether Bio-Techne (TECH) stock is underperforming the broader healthcare sector. It likely examines TECH's recent stock performance and compares it against relevant healthcare sector benchmarks. The analysis would aim to identify if the company's stock growth is lagging or keeping pace with its industry peers.

**4. Bio-Techne (NASDAQ:TECH) Downgraded to Strong Sell Rating by Zacks Research**
- Source: MarketBeat | 20251219T112700 | Bearish | Relevance: 100%
- Zacks Research has downgraded Bio-Techne (NASDAQ:TECH) from a "hold" to a "strong sell" rating, indicating near-term analyst pessimism, despite MarketBeat's consensus remaining a "Moderate Buy" with a $71.00 price target. The company reported Q earnings of $0.42, matching estimates, but revenue missed expectations at $286.6 million, a 1% year-over-year decrease. Bio-Techne's stock trades near $57 with a P/E of about 116.5 and a market capitalization of $8.9 billion.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 1, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-11-20 | Argus Research | $68 | $65 | +5% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-11-20 | Argus Research | main | Buy |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 8 ($0.00M) |
| Sells | 3 ($0.43M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 42.7% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 6 / 4 |

**Top Holders:**
- Vanguard Group Inc: 11.5% (-2.7%)
- Blackrock Inc.: 7.6% (-2.3%)
- Morgan Stanley: 4.7% (+10.0%)
- State Street Corpora: 3.7% (-1.8%)
- Wellington Managemen: 3.3% (+349.8%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 0.83 indicates undervaluation relative to growth. Forward P/E 26.8x stretched relative to 10% growth. Balance sheet: strong liquidity (4.2x), low leverage (D/E 0.29). Institutional flow bullish (6 buying vs 4 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $9.1B |
| Beta | 1.46 |
| 52W Range | $46.01 - $79.28 |
| Short Interest | 6.8% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.83 |
| Forward P/E | 26.8 |
| Current P/E | 29.5 |
| YoY Growth | 10.0% |
| EPS Direction | STABLE |

### Technicals

MRS_10 strengthening from -2.0% to -0.9% (+1.1% in 5 days), confirming momentum buildup. Below STRENGTH zone by 3.9pp (needs >3.0% for momentum thesis). Long-term uptrend intact (above SMA200 at 1.05x) but short-term weakness (below SMA20). MACD histogram bearish (-0.52), momentum weakening. RSI neutral at 44. OFD pattern: +MUH (Resistance test).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -0.90% (CS: 37) | Neutral |
| RSI_14 | 43.5 | Neutral |
| MACD Histogram | -0.52 | Bearish |
| vs SMA20 | 0.953x | Below |
| vs SMA50 | 0.956x | Below |
| vs SMA200 | 1.055x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $58.27
- **Stop Loss:** $54.11 (7.1% risk)
- **Target:** $62.43 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 288
- **Position Value:** $16,781.76
- **Portfolio %:** 16.78%
- **Risk Dollars:** $1,200.00
- **Risk Per Trade:** 1.20%
- **Modifiers:** L1 120% | L2 100% | Combined 1.20x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.20x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with improving risk appetite as VIX falls to 6th percentile and tech rally resumes on AI infrastructure demand. Fed pause expectations from cooling CPI data support equities, though elevated put/call ratio suggests cautious positioning. Focus on quality names in AI-exposed sectors.*

### Earnings

**Next:** 2026-02-09 (Est: $0.43)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $0.42 | $0.42 | -0.4% |
| 2025Q2 | $0.50 | $0.53 | +5.8% |
| 2025Q1 | $0.51 | $0.56 | +10.4% |
| 2024Q4 | $0.39 | $0.42 | +7.8% |

---
*RULE-based L3 | 2026-01-06 16:38 | MRS_10*